Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.

Cite

CITATION STYLE

APA

Hanzel, J., Dreesen, E., Vermeire, S., Löwenberg, M., Hoentjen, F., Bossuyt, P., … Mathôt, R. (2022, May 1). Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143). Inflammatory Bowel Diseases. Oxford University Press. https://doi.org/10.1093/ibd/izab270

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free